Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00729807 · ClinicalTrials.gov registry record · Phase 2
0794GCC: Pentamidine in Treating Patients With Relapsed or Refractory Melanoma
A Phase 2 study, sponsored by University of Maryland, Baltimore.
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT00729807 is a Phase 2 study that was terminated before completion, run by University of Maryland, Baltimore. The registered enrollment target is 6 participants.
The verdict
NCT00729807, a Phase 2 study, was terminated before completion, sponsored by University of Maryland, Baltimore.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as pentamidine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well pentamidine works in treating patients with relapsed or refractory melanoma.
Interventions
- DRUG pentamidine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2008-07 |
| Est. Completion | 2012-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00729807
The ClinicalTrials.gov registry entry for NCT00729807 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which pentamidine is the first listed.
NCT00729807 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00729807 about?
NCT00729807 is a clinical study titled "0794GCC: Pentamidine in Treating Patients With Relapsed or Refractory Melanoma". RATIONALE: Drugs used in chemotherapy, such as pentamidine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well pentamidine works in treating patients with relapsed or refractory m...
What is the current status of trial NCT00729807?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2008-07. Estimated completion is 2012-11.
What interventions are being tested in trial NCT00729807?
The interventions under investigation include: pentamidine (DRUG).
Who is sponsoring clinical trial NCT00729807?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.